With its innovative Clinical Trials Network, influential annual meeting and high-impact journals, SNMMI encourages and facilitates research and science for the nuclear medicine and molecular imaging field. Learn more.

Clinical Trials Network

The Clinical Trials Network (CTN) provides tools and resources to promote faster, more cost-effective drug development and increase the availability and performance of molecular imaging radiopharmaceuticals for use in the clinic. Our Mission is to advance the use of molecular imaging agents in clinical trials through standardization of chemistry and imaging methodology. This includes using imaging radiopharmaceuticals during the course of drug development, as well as bringing new radiopharmaceuticals to regulatory approval. Programs developed over the past 5 years include a comprehensive registry of qualified imaging sites and radiopharmaceutical manufacturers, a robust scanner validation program, access to standardized imaging protocols and a very strong clinical research education curriculum.


  • March 5, 2018Novel PET Imaging Agent Targets Copper in Tumors, Allowing Early Detection of Prostate Cancer Recurrence
    An Italian study featured in the March issue of The Journal of Nuclear Medicine demonstrates that a novel nuclear medicine imaging agent targeting copper accumulation in tumors can detect prostate cancer recurrence early in patients with biochemical relapse (rising prostate-specific antigen [PSA] level).
  • March 5, 2018JNMT: New Cover, New Features
    The Journal of Nuclear Medicine Technology (JNMT) has a new cover design and new features under the leadership Kathy Thomas, MHA, CNMT, whose five-year term as editor began in January.
  • March 1, 2018Researchers Develop New Approach That Uses a Single PET Scan to Personalize Cancer Treatment
    Researchers have developed a same-day, noninvasive PET-based imaging approach to assess PD-L1 positive tumors, which could help guide cancer treatment decisions and assess treatment response. The study is presented in the featured article of The Journal of Nuclear Medicine’s March issue.
  • February 13, 2018SNMMI and ASNC Issue Joint Guidelines for Quantification of Myocardial Blood Flow Using PET
    SNMMI's Cardiovascular Council and the American Society of Nuclear Cardiology (ASNC) have issued the joint position paper, Clinical Quantification of Myocardial Blood Flow Using PET, which was jointly published in the Journal of Nuclear Cardiology and The Journal of Nuclear Medicine.
  • February 5, 2018PSMA PET/CT Clearly Differentiates Prostate Cancer from Benign Tissue
    Using nuclear medicine, German researchers have found a way to accurately differentiate cancerous tissue from healthy tissue in prostate cancer patients. The research is highlighted in the February issue of The Journal of Nuclear Medicine.
  • February 1, 2018PSMA PET/CT Visualizes Prostate Cancer Recurrence Early, Impacts Radiation Therapy
    A nuclear medicine scan may locate prostate cancer recurrence after radical prostatectomy early after disease recurrence and could help guide salvage radiotherapy, according to new research from the University of California Los Angeles (UCLA). The study, which utilizes PET/CT with gallium-68 prostate-specific membrane antigen (68Ga-PSMA-11), is documented in the featured article in the February issue of The Journal of Nuclear Medicine.
  • January 8, 2018Novel PET Tracer Clearly Identifies and Tracks Bacterial Infection in Lungs
    Researchers at the University of Louisville, Kentucky, have demonstrated that a new radiotracer, F-18-FDS, can identify and track bacterial infection in lungs better than current imaging methods and is able to differentiate bacterial infection from inflammation. The study is the featured basic science article in the January issue of The Journal of Nuclear Medicine.
  • January 4, 2018SNMMI Publishes Appropriate Use Criteria for Somatostatin Receptor PET Imaging
    SNMMI has published appropriate use criteria (AUC) for somatostatin receptor PET imaging in neuroendocrine tumors (NETs), addressing several clinical scenarios for diagnosing NETs. This AUC is part of a new series developed by SNMMI in its role as a qualified provider-led entity under the Medicare Appropriate Use Criteria Program for Advanced Diagnostic Imaging.

Preclinical Imaging

CMIIT’s mission is to engage the molecular imaging community and leverage the SNMMI infrastructure to advance the adoption of emerging molecular imaging technologies and probes in preclinical and clinical applications. One of the goals is to develop educational resources for a “translational researcher”. CMIIT will provide researchers with needed education and training on the “nuts and bolts” of translating and transitioning an agent or technique from pre-clinical research into the clinical practice such as tracer development, equipment, and funding.

The Nuclear Medicine Clinical Trial Group, LLC

Under the auspices of the Society of Nuclear Medicine and Molecular Imaging, the Nuclear Medicine Clinical Trial Group(NMCTG) assists industry partners and academic investigators in managing clinical research activities.  Its goals include ensuring quality imaging is conducted in drug or diagnostic clinical trials and providing training for molecular imaging professionals performing clinical research. Many of the programs established under the Clinical Trials Network, such as its robust Education Program, provide support to the NMCTG to help carry out its mission.